Form 4: Processa Pharmaceuticals Executive Sian Bigora Reports Stock Transactions
SEC Form 4 Filing
Sian Bigora, Chief Development Officer of Processa Pharmaceuticals, reports the acquisition and disposal of common stock, including a distribution of vested restricted shares.
Summary
- On April 1, 2025, Sian Bigora, Chief Development Officer of Processa Pharmaceuticals, engaged in transactions involving the company's common stock.
- Bigora acquired 15,059 shares through the vesting of restricted shares.
- Bigora disposed of 3,311 shares at a price of $0.412 per share.
- Following these transactions, Bigora directly owns 33,626 shares of common stock.
- Bigora also indirectly owns 6,668 shares through CorLyst, LLC.
Sentiment
Score: 5
Explanation: This is a neutral regulatory filing. The transactions themselves don't necessarily indicate positive or negative sentiment about the company's future prospects.
Industry Context
This is a standard SEC Form 4 filing, which is a routine disclosure of stock transactions by company insiders. It provides transparency into the trading activities of individuals with access to non-public information.
Key Dates
| Date | Description |
|---|---|
| 04/01/2025 | Date of common stock transactions (acquisition and disposal). |
| 04/11/2025 | Date of report filing. |
Keywords
Form 4, Beneficial Ownership, Stock Transactions, Processa Pharmaceuticals, Sian Bigora, PCSA, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.